Latest Breaking News On - எங்களுக்கு மருந்துகள் - Page 7 : comparemela.com

The performance of most pharmaceutical stocks has been underwhelming over the past year. The benchmark  iShares US Pharmaceuticals ETF (NYSEMKT:IHE) has underperformed the S&P 500 by almost 20% in this time, and some companies in particular look especially cheap. Their share prices have not kept pace with the broader bull market, and that presents a bargain opportunity for investors. Two big-name pharmaceuticals that have been making news a lot lately, much of that related to the COVID-19 pandemic, are Gilead (NASDAQ:GILD) (Pfizer with a vaccine in partnership with BioNTech, Gilead with a treatment called remdesivir). But while both have made COVID-related headlines, neither has seen a COVID-related boost both stocks are at a price-to-earnings ratio of less than 15, which is cheap from a valuation perspective in comparison to many peers. (

Gilead sciencesWorld health organizationDrug administrationUs pharmaceuticalsEli lillyImage sourceகிலியட் அறிவியல்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்எங்களுக்கு மருந்துகள்எலி லில்லிபடம் மூல